Peter builds on more than 20 years of pharma and biotech experience to drive Mammoth’ Biosciences’ corporate strategy for therapeutics and diagnostics. The motivation of his function is the translation of next generation CRISPR technology into applications to improve all lives. The team covers partnering, alliance management and product management. Peter joined Mammoth from Casebia Tx which he co-founded as a JV between Bayer and CRISPR Tx leading to several assets at preclinical stage at the time of acquisition by CRISPR Tx. Prior to Casebia, Peter has been at Bayer Healthcare in various positions in US and Germany covering strategic marketing, BD&L, project management, operations, and R&D in various indication fields. Peter completed postdoctoral studies at Stanford University after receiving his Ph.D. in Organic Chemistry from the University of Marburg. He studied chemistry at the Universities of Heidelberg, Bristol and Freiburg. Peter is co-inventor of Letermovir and Neladenoson.